Thermo Fisher Scientific Inc. Q3 2025 Earnings Recap

TMO Q3 2025 October 22, 2025

Get alerts when TMO reports next quarter

Thermo Fisher Scientific demonstrated solid operational performance in Q3 2025, achieving a 5% revenue increase to $11.12 billion and raising full-year guidance due to strong growth in its bioproduction and analytical instruments segments.

Earnings Per Share Beat

$5.79 vs $5.50 est.

+5.3% surprise

Revenue Beat

11122000000 vs 10917924591 est.

+1.9% surprise

Market Reaction

1-Day +0.83%

5-Day -1.57%

30-Day +3.58%

See TMO alongside your other holdings

Add to your portfolio — free

Key Takeaways

Adjusted operating income rose 9% to $2.59 billion, while adjusted EPS grew 10% to $5.79 per share.
Pharma and biotech revenue maintained mid-single-digit growth, supported by strong contributions from bioproduction and analytical instruments.
Diagnostics and Healthcare revenue showed improvement, though it remained down low single digits due to challenging conditions in China.
Continued innovation highlighted by FDA approvals for clinical genomic tests and new launches in proteomics and electron microscopy.
Strengthened customer relationships through strategic collaborations, including a notable partnership with OpenAI.

This summary was generated by AI from the official earnings call transcript and is provided for informational purposes only. It does not constitute financial advice. For the complete transcript and financial data, visit TMO on AllInvestView.

Next Q1 2026